Gap Junction Dysfunction Validation in Parkinson's Disease

V2, Crosslink

🧫

Gap Junction Dysfunction Validation in Parkinson's Disease

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-gap-junc

🧫 Experiment Protocol Clinicalproposed

SUMMARY

# Gap Junction Dysfunction Validation in Parkinson's Disease ## Background and Rationale Gap junction dysfunction represents an emerging frontier in Parkinson's disease pathophysiology, offering a compelling mechanistic framework that bridges cellular communication deficits with the complex cascade of neurodegeneration characteristic of this debilitating movement disorder. This clinical investigation probes the fundamental hypothesis that compromised connexin and pannexin channel function serves

METHODOLOGY NOTES

**Phase 1: Patient Recruitment and Baseline Assessment (Weeks 1-8)** • Recruit 120 Parkinson's disease patients (Hoehn & Yahr stages II-IV) and 60 age-matched healthy controls • Obtain informed consent and perform comprehensive neurological evaluation using UPDRS-III • Collect detailed medical history, medication records, and cognitive assessment (MoCA) • Perform baseline brain MRI with dopamine transporter (DAT) imaging • Collect cerebrospinal fluid (CSF) samples via lumbar puncture (n=60 PD, n=30 controls) • Collect blood samples for plasma biomarker analysis **Phase 2: Gap Junction Protein Analysis (Weeks 3-12)** • Analyze CSF and plasma connexin-43 (Cx43) and pannexin-1 (Panx1) levels using ELISA • Measure gap junction functionality markers: connexin phosphorylation status via Western blot • Quantify pannexin-1 channel activity using ATP release assays in isolated PBMCs • Assess connexin-43 protein expression and localization in available post-mortem brain tissue (n=20) • Perfor

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.906792Z'}
summary	# Gap Junction Dysfunction Validation in Parkinson's Disease ## Background and Rationale Gap junction dysfunction represents an emerging frontier in Parkinson's disease pathophysiology, offering a com
entities	{'genes': ['GAP43/GJA1/RAB27A'], 'diseases': ["Alzheimer's Disease"]}
model_system	human
_schema_version	1
experiment_type	clinical
primary_outcome	Validate Gap Junction Dysfunction Validation in Parkinson's Disease
methodology_notes	Phase 1: Patient Recruitment and Baseline Assessment (Weeks 1-8) • Recruit 120 Parkinson's disease patients (Hoehn & Yahr stages II-IV) and 60 age-matched healthy controls • Obtain informed conse
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.906798', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

568

Outgoing

520

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Gap Junction Dysfunction Validation in Parkinson's Disease

derives from (16)

supports (5)

💬 Discussion